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Background
Serbia is one of the leading countries in the world with
respect to mortality from cardiovascular diseases. Drugs
that reduce serum lipids belong to the group of drugs
that can significantly lower complications of cardiovas-
cular diseases and their utilization in Serbia deserves
special attention. The aim of this study was to measure
the consumption of serum lipid reducing drugs in Serbia
from 2004 to 2010, to compare these data with those
from Scandinavian countries, and to compare the con-
sumption of lipid-lowering drugs and the rate of mortal-
ity from cardiovascular diseases in these countries.
Methods
A population-based study was undertaken to analyse
lipid-lowering drug consumption using the Anatomical
Therapeutic Chemical/Defined Daily Dose methodology.
Cause-specific mortality rates were obtained from the
WHOSIS annual report for the year 2009.
Results
In 2010, a total of 966 DDD/1000 inh/day (DID) of all
drugs, was used in Serbia, of which 38.9% belonged to
drugs for cardiovascular diseases. While in Scandinavian
countries 17.0–24.8% of drugs for cardiovascular diseases
belonged to lipid-lowering drugs, in Serbia it was sub-
stantially lower (3%). In 2004 in Serbia, 1.50 DID of sta-
tins were used. In 2008, this value was 32.5 DID. In every
investigated country, simvastatin made up more than
50% of the consumption of statins. After simvastatin, the
next most frequently used statin was atorvastatin, with
5.52, 11.0, 11.2 and 24.8 DID, in Serbia, Denmark,
Finland and Norway, respectively. In 2004 Serbia had the
highest mortality rate for cardiovascular diseases among
the investigated countries with 762/100.000 inhabitants
and Norway has the lowest rate with 158/100.000
inhabitants.
Conclusions
The use of lipid-lowering drugs is 6–8 times lower in
Serbia as compared to Scandinavian countries but there
is an evident rise in lipid lowering drugs consumption
in Serbia during the investigated years.
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